News
-
-
PRESS RELEASE
Applied DNA Receives Approval for TR8(TM) Pharmacogenomic (PGx) Testing Service from New York State Department of Health
Applied DNA Sciences, Inc. receives approval from NYSDOH for TR8 PGx testing service targeting enterprise customers and healthcare networks in New York State, offering personalized medication guidance based on genetic testing -
-
-
-
PRESS RELEASE
Applied DNA Announces Pricing of $12 Million Public Offering
Applied DNA Sciences, Inc. announces pricing of public offering expected to raise $12.0 million. Offering includes Common Shares, Pre-Funded Warrants, Series A and Series B Warrants. Proceeds to support company's services and general purposes -
-
PRESS RELEASE
Institute of Hematology and Blood Transfusion (Prague) to Present on Successful Use of Applied DNA's Linea DNATM for the Non-Viral Manufacture of CAR T-Cell Therapy for Refractory AML
Applied DNA Sciences and IHBT announce abstract on enzyme-based CAR T-cell therapy manufacturing to be presented at EHA 2024 Congress. The study focuses on virus-free CD123-specific CAR T-cells using Linea DNA -
-
PRESS RELEASE
Applied DNA Announces Second Quarter Fiscal Year 2024 Financial Results
Applied DNA Sciences, Inc. announces Q2 fiscal 2024 financial results, reporting a decrease in revenues due to COVID-19 testing decline. Operating expenses decrease and loss from operations increases. Stock split completed and Nasdaq compliance regained
